NCT01448304View on ClinicalTrials.gov

Study of the Tolerability, Safety, Pharmacokinetics and Pharmacodynamics of Alirocumab SAR236553 (REGN727)

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

June 30, 2011

Primary Completion Date

September 30, 2011

Study Completion Date

September 30, 2011

Conditions
Hypercholesterolemia
Interventions
DRUG

alirocumab SAR236553 (REGN727)

Pharmaceutical form:Solution Route of administration: Subcutaneous

Trial Locations (1)

Unknown

Sanofi-Aventis Administrative Office, Bridgewater

Sponsors

Lead Sponsor

Sanofi
All Listed Sponsors
collaborator

Regeneron Pharmaceuticals

INDUSTRY

lead

Sanofi

INDUSTRY